The effects of the adenosine deaminase inhib itor, deoxycoformycin, on purine release from the rat ce rebral cortex were studied with the cortical cup tech nique. Deoxycoformycin (5 and 500 j..L g/kg i.v.) enhanced the hypoxia/ischemia-evoked release of adenosine from the cerebral cortex, indicating a marked rise in the aden osine content of interstitial fluid in the cerebral cortex. Inosine and hypoxanthine release were attenuated at the higher dose of deoxycoformycin. Uric acid release into the cortical perfusates was enhanced at the higher dose level. These results demonstrate that low doses of de oxAttention has recently been focused on the role of adenosine as a regulator of CBF during hypoxia/ ischemia (Berne et aI. , 1974(Berne et aI. , , 1983 Phillis et aI. , 1984 Phillis et aI. , , 1985b Morii et aI. , 1987). Adenosine is a po tent cerebral vasodilator (Morii et aI. , 1986) and is released into the interstitial space of the brain during hypoxia and ischemia (Zetterstrom et aI. , 1982; Van WyIen et aI. , 1986; Phillis et aI. , 1987).
ycoformycin can be used to elevate interstitial levels of adenosine in the brain during hypoxia, and to depress the formation of some of its metabolites. The elevation of hypoxia/ischemia-evoked adenosine levels can account for the previously reported potentiation of hypoxia evoked increases in rat cerebral blood flow after deoxy coformycin administration. The potential therapeutic utility of these findings is discussed. Key Words: Deoxy coformycin -Adenosine-Purines, release-Cerebral cortex-Hypoxia.
in rat brains (Phillis et aI., 1984 (Phillis et aI., , 1985a . Likewise, inhibition of the enzyme adenosine deaminase, which converts adenosine into the inactive metabo lite inosine, with two potent and specific inhibitors of this enzyme deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) also potentiated hypoxia-induced hyperemia of the rat brain (Phillis et aI. , 1985b) .
The aim of the present experiments was to dem onstrate that the inhibition of adenosine deaminase by deoxycoformycin does in fact result in elevated levels of adenosine in the interstitial spaces of the brain during hypoxic challenges. This objective was achieved by measuring the release of adenosine and its metabolites into artificial CSF perfusates of the rat cerebral cortex. Adenosine levels in the cere bral perfusates during and after hypoxic challenges were elevated after deoxycoformycin administra tion. Somewhat unexpectedly, inosine levels in the perfusates were not consistently reduced, although those of hypoxanthine declined.
METHODS

Animal preparation
Adult male Sprague-Dawley rats weighing 350-500 g were anesthetized with halothane. After tracheal cannu-lation, anesthesia was maintained with methoxyflurane in air. Body temperature was maintained at 3rC with a heating pad controlled by a rectal probe. One femoral ar tery was cannulated for measurement of arterial blood pressure (Statham pressure transducer) and the with drawal of arterial blood samples for blood gas and pH analysis.
The animal's heads were then placed in a Narashige SH-8 nontraumatic headholder and the dorsal and dorso lateral surfaces of both cerebral hemispheres were ex posed by careful removal of the overlying frontal and pa rietal bones. A thin strip of bone was left intact along the midline to protect the dorsal sagittal venous sinus. The dura mater-arachnoid membrane complex overlying both hemispheres was carefully incised and reflected to expose the brain. Complete hemostasis was essential to prevent contamination of the artificial CSF with red blood cells and platelets, which are capable of releasing adenine nucleotides and adenosine in sufficient amounts to aff ect estimates of adenosine and inosine in perfusates (German and Kredich, 1984) . Rectangular cortical cups suspended in flexible mounting brackets (Phillis et al., 1987) were then lowered onto both cortices, so that the frontal, parietal, and occipital cortical surfaces were ex posed within the cups. Each cup was then filled with an artificial CSF solution to ensure that there was no leakage of fluid. The dorsal surface of the head was cov ered with a mixture of 4% agar in artificial CSF to stabi lize the cups and protect the exposed tissue from drying. The artificial CSF consisted of Na+ 155.8 mEq/L; K+ 2.95 mEq/L; Ca 2 + 2.5 mEq/L; Mg 2 + 1.85 mEq/L; Cl-141.13 mEq/L; HC03 -22 mEq/L; dextrose 66.5 mgldl; and urea 40.2 mgldl. The osmolarity of this solution was 302 mOsmiL. The fluid was equilibrated for several hours with a gas mixture of 5% CO2, 5% O2 in 90% N and warmed to 37°C. After equilibration the CSF averaged a Peo2 of 38.4 ± 0.6 and a P02 of 48.2 ± 2.8 mm Hg. Ad justment of pH was made, if necessary, to 7.3 with so dium bicarbonate. PE 10 polyethylene tubing was used to convey the same gas mixture into both cortical cups to create a barrier between the perfusate and the external atmosphere. CSF samples withdrawn after 10 min of equilibration with the cerebral cortex had a mean P02 of 57.8 ± 3.5 and Peo2 of 33.7 ± 0.1 mm Hg at pH 7.34 ± 0.02. Feng et al. (1988) have recorded a mean P02 value of 44 mm Hg with electrodes at the surface of a "closed skull" rat cerebral cortex.
Measurement of purines in artificial CSF
The chromatographic system consisted of Waters As sociates: M6000A pump, U6K injector, RCM-IOO radial compression module with Resolve C18 5 J-Lm stationary phase cartridge, 450 absorbance detector set at a detec tion wavelength of 260 nm and a Spectra-Physics 4270 integrator. The CSF samples collected from the animals were centrifuged (1,200 g, 5 min, 4°C) and the supernates injected directly into the HPLC system without extrac tion or deproteination. To protect the system from clog ging with particulate matter, a Waters In-Line filter with 0.2 J-Lm pore size and a Waters Guard-Pak with Resolve C18 precolumn insert were incorporated into the HPLC system upstream of the stationary phase column.
Two separate moving phase compositions were em ployed in this study. A moving phase consisting of 0.22 M, pH 5.8 phosphate buffer alone, was used to resolve for hypoxanthine, xanthine, and uric acid. The moving J Cereb Blood Flow Me/ab, Vol. 8, No.5, 1988 phase composition used to resolve adenosine and inosine consisted of: 0.22 M, pH 6.8 phosphate buffer, 7% (voll vol) methanol, 2.5 mM tetrabutylammonium phosphate (Waters PIC-A). Both moving phases were degassed by filtration under vacuum (Millipore type HA) prior to use. Individual standard curves for adenosine, inosine, hypo xanthine, xanthine, and uric acid were constructed using known amounts of standard injected versus the observed chromatographic peak areas or heights. Injection volumes were 50 J-Ll of CSF for hypoxanthine, xanthine, and uric acid determinations and 100 J-Ll for adenosine and inosine measurements. Substance identification was by retention time. Confirmation of substance identity was obtained by enzymatic degradation using adenosine de aminase, nucleoside phosphorylase, xanthine oxidase or uricase (Sigma Chemical Co., St. Louis, MO, U.S.A.). The minimum detectable amount of adenosine and ino sine was 1.0 pmol, which with a 100 J-Ll injection volume corresponds to a minimum detection concentration of 10 nM. The minimum detectable concentration of hypoxan thine, xanthine, or uric acid was 100 nM.
Experimental procedures
Each animal was subjected to a series of challenges during which it inhaled a 5% O2 in nitrogen gas mixture for 10 min. A fixed schedule was followed in all experi ments. Two hundred microliters of artificial CSF was placed in each cup for 10 min. At the expiration of the collection period, this fluid was withdrawn with a Pasteur pipette and replaced with another 200 J-Ll aliquot. The col lected fluid was ejected into a chilled micro vial inserted into an ice container, centrifuged for 5 min at 1,200 g to remove any particulate matter, and then stored at -20°C until assayed. After two control collections, the animal was exposed to the 5% O2 mixture for 10 min and the perfusate was collected. The cups were refilled immedi ately and two further collections were obtained during normoxic gas mixture inhalation. Deoxycoformycin (5 J-Lglkg or 500 J-Lg/kg) in 0.9% saline was administered in travenously at this point and a 15-min interruption of the collection sequence was scheduled to allow for absorp tion. Following a lO-min basal release collection, the an imal was exposed to a second lO-min hypoxic challenge; three normoxic collection periods with a lO-min interlude between the second and third perfusate collections; a third hypoxic challenge and the experiment was termi nated after two further normoxic collection periods. To eliminate delays in the onset of hypoxia, two British Ox ygen Corporation vaporizers were used for methoxy flurane and gas mixture administration. The 5% O2 mix ture in nitrogen was flushed through the second vaporizer for several minutes prior to connection to the animal, so that the onset of hypoxia was immediate.
Eight rats that received an intravenous injection of sa line were used for control studies to establish the repro ducibility of the purine releases evoked by the hypoxic challenges; five rats received deoxycoformycin (5 J-Lglkg) and seven rats were administered deoxycoformycin (500 J-Lglkg).
Statistical analysis
Student's t test for paired samples was used for statis tical comparisons of the mean values of prehypoxia, basal, purine release with those measured during, and posthypoxia within the same groups of animals (Figs.
1-5).
A Student-Neuman-Keuls test for multiple-group com parison was used to determine differences between mean values for each postinjection collection period. These re sults are summarized in Ta ble 1. Deoxycoformycin treated groups were compared at both doses (5 f.Lg and 500 f.Lg/kg i.v.) with the control series, to separate drug effects from changes due to time. Additionally, responses to the high dose of deoxycoformycin were compared with equivalent collection periods after administration of the 5 f.Lg/kg dose. A p value of <0.05 was accepted as indi cating a statistically significant difference.
RESULTS
Hemodynamic values
MABP and blood gas values are presented in Table 2 . In all groups of animals the MABP fell sig nificantly during each of the hypoxic challenges. Within each group, however, the magnitude of the drops in MABP were generally consistent. The hy perventilation resulting from the hypoxia caused a lowering of P aC02, and an increase in blood pH, but these changes were again consistent within, and in most instances across, the groups of animals. Pa02 values recorded during the final minute of hypoxic challenges show that oxygen levels fell from control values of between 82.0 to 92.1 mm Hg to levels of 27.8-37. 6 mm Hg. The magnitude of the decreases of P a02 were consistent for each group of animals during the three hypoxic challenges.
Adenosine release
Ten-minute collection periods were used for these experiments because adenosine and inosine levels in the cortical perfusate achieve stable levels within this period (Phillis et aI. , 1987) . The results with adenosine release are summarized in Fig. 1 and Ta ble 1. Before the onset of hypoxia, perfusate adenosine levels in the control series of animals were 28.1 ± 3.8 nM. During the initial challenge, adenosine levels increased to 127.9 ± 47.2 nM (355% increase), remained at above control levels during the first recovery period, and returned to control levels during the second recovery period. A similar pattern of release was observed during the second and third hypoxic challenges, although the hypoxia-induced release was less pronounced during the third challenge.
Basal release levels were slightly higher in the animals used for the low-dose deoxycoformycin All values are means ± SEM. MABP values were calculated from the average of blood pressures of each animal recorded at 2 min intervals during the hypoxic challenge. pH and blood gas values were obtained from blood samples withdrawn 9 min after the onset of hypoxia.
series (38.3 ± 4.6 nM), and increased to 253.6 ± 67.3 nM during the control period of hypoxia. Ad ministration of deoxycoformycin (5 f.Lg/kg) did not alter basal levels of adenosine release, but did greatly increase the adenosine content of the per fusate during the first postdrug hypoxia (892.0 ± 189.3 nM), with an even further increase in release during the first recovery period. Adenosine levels were still above control during the second recovery period, but then returned to basal levels. The second postdrug hypoxia evoked an even greater increase in adenosine levels (1080.0 ± 204.5 nM), with a further increase in the first recovery period. Return to basal levels was delayed in comparison with the original controls.
A similar, but more striking, pattern of changes was observed after the higher dose of deoxycofor mycin (500 f.Lg/kg). Basal perfusate adenosine con centrations were not affected. The increases during and after postdrug hypoxic challenges were even more pronounced and of longer duration than those observed with the lower dose of deoxycoformycin. The maximum observed increase occurred during the first postdrug recovery period of the initial hyp oxia after the drug, with a 72-fold elevation of per fusate adenosine concentration to 2.78 ± 0.43 f.LM. 
Inosine release
Basal perfusate concentrations of inosine in the saline control series ranged from 76.4 ± 10.4 nM in the initial collections to 59.8 ± 0.2 nM before the third hypoxic challenge. Inosine levels were ele vated during and after the hypoxic challenges (Fig.  2) . The pattern of release was maintained during the subsequent two hypoxic periods, although there was some tendency for the increases in release to decline with successive challenges.
Basal levels of inosine release declined from 127.4 ± 21.3 nM to 78.2 ± 6.5 nM after the admin istration of deoxycoformycin (5 f-Lg/kg). The in creases in inosine content during hypoxic chal lenges were comparable to those observed in the saline-treated animals. The increase in inosine re lease after the hypoxic challenge was prolonged in the 5 f.Lg/kg deoxycoformycin-treated group. Dif ferent results were obtained with the higher dose of deoxycoformycin (500 f.Lg/kg). Although basal levels of inosine in the cortical perfusates were un altered or slightly elevated, hypoxia-evoked re leases of inosine were significantly lower in the 500 f.Lg/kg deoxycoformycin group compared with those observed with the lower dose. 
Hypoxanthine release
Basal hypoxanthine levels in the cortical per fusates of the saline control rats were stable during the initial period of the experiment (233. 3-238. 5 nM), but had declined (105. 2 nM) before the third hypoxic challenge. Each hypoxic challenge evoked a marked increase in the hypoxanthine content of the cortical perfusate, which became even more pronounced in the first recovery period (Fig. 3) . Release was still markedly above basal levels during the second recovery period, but had re turned to control levels before the onset of the next challenge. Deoxycoformycin (5 fJ-g/kg) did not alter the basal or hypoxia-evoked levels of hypoxanthine in cortical perfusates. The effects of the larger dose (500 fJ-g/kg) deoxycoformycin were pronounced. Although basal levels of hypoxanthine release were unaffected, the deoxycoformycin virtually abol ished the hypoxia-induced increases in release ( Fig.  3 ; Ta ble 1).
Xanthine
Basal levels of xanthine in cortical perfusates of the saline control series were initially 536.9 ± 122. 7 nM and declined to 405. 0 ± 84. 3 nM before the third challenge. During hypoxic challenges, per fusate levels increased considerably, reaching con centrations in excess of 1 fJ-M during the first two challenges. Recovery occurred slowly, but levels had reverted to basal before the next challenge. Deoxycoformycin (5 fJ-g/kg) had no apparent effect on either basal or evoked release of xanthine.
After deoxycoformycin (500 fJ-g/kg), although basal perfusate concentrations of xanthine were unaffected, there were no longer any significant in creases in the levels of xanthine in response to hyp oxic challenges (Fig. 4) .
Uric acid release
Basal uric acid levels in the cortical perfusates of the control series animals were in the range of 1, 678. 8-1,917. 5 nM (Fig. 5 ). Significant increases in perfusate concentrations were observed during and after the hypoxic challenges. Recovery to basal levels was slow after each challenge, but had oc curred before the next hypoxia. Deoxycoformycin (5 f.Lg/kg) did not affect basal levels of uric acid release, but tended to magnify the hypoxia-evoked release both during and imme diately after each challenge (Fig. 5) . More striking results were obtained after deoxycoformycin (500 f.Lg/kg) administration. In these animals uric acid levels were significantly higher after treatment with 500 f.Lg/kg deoxycoformycin as compared with the lower dose.
DISCUSSION
The present investigation confirms our earlier re port (Phillis et aI., 1987) and uric acid (1,000-1,700 nM). The levels of aden osine, inosine, hypoxanthine, and xanthine are comparable to those measured in endogenous CSF obtained from the rat cisterna magna (adenosine 35 ± 9 nM (SEM); inosine 359 ± 85 nM; hypoxan thine 243 ± 77 nM, xanthine 1, 340 ± 423 nM; Walter et aI., 1988) . The level of uric acid in the cortical perfusates was lower than that in endoge nous CSF (6, 130 ± 678 nM). Rat blood levels of uric acid are even higher (49.8 ± 21.1 f.LM) (G. A. Walter, unpublished observations). The basal levels of adenosine and its metabolites present in these cortical superfusates are one to two orders of magnitude lower than those recorded in microdialysate samples from the rat striatum (Zetterstrom et aI., 1982; Van Wylen et aI., 1986; Hagberg et aI., 1987) . The potential reasons for this discrepancy have been addressed in our earlier ar ticle (Phillis et aI., 1987) . A likely cause is the tissue trauma and occlusion of adjacent blood vessels caused during the insertion of the dialysis probe. The short-term disturbances of cerebral blood flow and metabolism at the site of implantation of dial ysis probes have recently been emphasized by Ben veniste et ai. (1987) . Indeed, Fredholm (1987) has now reported that some 4-8 h after insertion of the dialysis probe it became impossible to detect aden osine and some other nucleosides in the dialysate. This was interpreted as evidence of microglial sheathing of the probe, and that the microglia by their potent salvage pathway cleared the extracel lular fluid of purine nucleoside. An alternative ex planation would be that after this period revascu larization and cell repair had reduced the trauma induced release of adenosine to undetectable levels. In a recent review of the scope and limita tions of in vivo brain dialysis, Westerink et ai. (1987) stress that release studies should not be con ducted on the day of probe implantation, due to transmitter release from damaged nerve terminals. Further support for the validity of our estimates of interstitial fluid adenosine and inosine in anesthe tized rat brains using the cortical cup technique comes from the observation that the hypoxia-in duced releases were considerably greater (34-to 38-fold; Phillis et aI., 1987) than the threefold in crease observed by Zetterstrom et ai. (1982) or 10-fold increase (Van Wylen et aI., 1986) using compa rable levels of hypoxia. This difference may be largely due to the higher basal levels of release in the dialysis experiments, because the levels of adenosine present in the cortical superfusates during hypoxia in the present experiments were very similar to those observed in the dialysis exper iments with comparable hypoxias. This finding re-inforces the conclusion that adenosine levels in cortical surface perfusates closely reflect those in cortical interstitial fluid.
As previously reported (Phillis et aI., 1987) , ex posure of rats to a 10-min period of hypoxia/isch emia resulted in an elevation of adenosine and ino sine concentrations in the cortical perfusates. The concentrations of hypoxanthine, xanthine, and uric acid also increased. These increases were apparent both during and after the actual period of hypoxia. Return to basal levels occurred within 30 min of the hypoxic challenge. Exposing rats to this degree of hypoxia not only decreased Pao2 but also resulted in hypotension and a moderate hypocapnia. The latter two conditions have been associated with in creases in brain adenosine (Winn et aI., 1980 (Winn et aI., , 1981 and could have contributed to the elevated levels of adenosine in the cortical perfusates. A hypotension of this magnitude does not, however, enhance the release of adenosine from the rat cerebral cortex (Phillis et aI., 1987) . Controlled studies on the ef fects of hypocapnia on adenosine release have not been undertaken, but is unlikely to have been a factor in the interpretation of the findings in these experiments with deoxycoformycin, because the drop in P aco2 was comparable in the predrug con trols used in statistical comparisons.
Deoxycoformycin was tested at two dose levels. Geiger et ai. (1987) have recently demonstrated that an intraperitoneal dose of 492 j.Lg/kg produces a 90-95% inhibition of rat brain adenosine deami nase. The 500 j.Lg/kg dose used in the present ex periments was selected on the basis of this report. The choice of a 5 j.Lg/kg dose was based on an ear lier study in which a 1 j.Lg/kg dose of deoxycofor mycin was observed to cause a significant prolon gation of the duration of the reactive hyperemia of rat CBF evoked by a brief period of hypoxia (Phillis et aI., 1985b) . At both dose levels, although there was no change in basal levels of adenosine in the cortical perfusates, the rate of release during and after hypoxic challenges was significantly enhanced above those of the predrug controls (Fig. 1 , Table  1 ). The magnitude of the increases was greater after the larger dose of deoxycoformycin.
At a dose of 5 j.Lg/kg, deoxycoformycin did not alter the basal levels of inosine release and in creases elicited by the second and third hypoxic challenges were comparable to predrug levels. This is in contrast to the gradual decrease in evoked level of inosine apparent over time in the control series. The magnitude of hypoxia-evoked release of inosine was reduced by the higher dose of deoxy coformycin, reaching significance during the first postdrug challenge. Deoxycoformycin, at the higher dose, reduced the hypoxia-evoked increases in hypoxanthine re lease (Fig. 3, Ta ble 1 ). These reductions were pro nounced, with virtually no hypoxia-induced in creases being apparent. Conversely, deoxycofor mycin, at 500 j.Lg/kg, appears to have potentiated the hypoxia-evoked release of uric acid into the cortical perfusates. Hypoxia-evoked xanthine re lease was also depressed (Fig. 2) , although the re ductions were not statistically significant.
The enhancement of adenosine release by deoxy coformycin (5 j.Lg/kg) is comparable to an earlier finding that inhibition of adenosine deaminase with EHNA enhanced hypoxia-evoked adenosine re lease with a decreased inosine release, from the caudate nucleus (Zetterstrom et aI., 1982) and is consistent with our previous demonstration that low doses of adenosine deaminase inhibitors are able to potentiate adenosine-mediated phenomena, namely, CBF reactive hyperemia during and after brief periods of anoxia (Phillis et aI., 1985b) . There was no change in the normoxic levels of adenosine in the perfusates. Interestingly, the increase in adenosine release with the low dose of deoxycofor mycin was not associated with a decrease in the basal or hypoxia-evoked release of inosine, al though a decrease in the challenge-elicited release of inosine was observed after the higher dose of deoxycoformycin. Because inhibition of adenosine deaminase by 5 j.Lg/kg deoxycoformycin (which would be equivalent to a concentration of 20 nM if evenly distributed throughout the body: a Ki of 0.18 nM has been reported for rat cerebral cortical ho mogenates; Skolnick et aI., 1978) did not alter basal or evoked inosine release, it is possible that, under these conditions, deamination of adenosine is not a major source of inosine, which may be derived pre dominantly from inosine 5'-monophosphate by the action of adenylate deaminase. Similar conclusions have been drawn from studies on the isolated guinea pig heart or on guinea pig cardiomyocytes in which AT P breakdown to inosine is unaffected by the inhibition of adenosine deaminase with EHNA (Schrader, 1983; Nees et aI., 1987) . The decrease in inosine formation observed after the higher dose of deoxycoformycin is likely to have been a result of the inhibition of brain adenylate deaminase (Sada sivudu et al., 1980) by this agent (Agarwal and Parks, 1977) .
The decreases in hypoxia/ischemia-elicited re leases of hypoxanthine and xanthine are more diffi cult to account for, although the decline in inosine formation after the high dose of deoxycoformycin may provide a partial explanation. The enzymes that metabolize inosine to hypoxanthine, xanthine, and uric acid (nucleoside phosphorylase, xanthine oxidase) are concentrated in brain capillaries (Mistry and Drummond, 1986; Betz, 1985) , raising the possibility that inosine must enter the capillary endothelial cells before its degradation. A recog nized action of deoxycoformycin at higher concen trations is inhibition of nucleoside transport (Hen derson et al., 1977; Newby, 1981) and it is possible that a block of inosine transport into the capillary endothelial cells could account for most of the re duction in hypoxanthine levels after the high dose of deoxycoformycin. A similar scheme has been proposed for the degradation of adenosine and ino sine released by cardiac muscle cells. The largest portion of these purines is subsequently taken up by the coronary capillary endothelium, where they are metabolized by intracellular enzymes, mainly to uric acid (Schrader, 1983; Dendorfer et al., 1987) . In the cardiomyocyte, which contains only low levels of adenosine deaminase, much of the release of purine is as AMP or adenosine . Neuronal or glial adenosine deaminase levels are likely to be higher (Geiger and Nagy, 1986) , with inosine formation occurring in nonendothelial as well as in capillary endothelial cells.
Uric acid release was, paradoxically, enhanced after deoxycoformycin administration. Because uric acid can also be formed by direct synthesis from 5-phosphoribosyl pyrophosphate and gluta mine, inhibition of adenosine metabolism would not necessarily cause a reduction in tissue levels of this substance. The increase in release remains to be explained.
In summary, therefore, inhibition of adenosine deaminase by deoxycoformycin resulted in the an ticipated increase in adenosine levels in cerebral cortical perfusates and decreases in perfusate con tents of inosine and hypoxanthine. Uric acid levels increased. These findings are of potential thera peutic importance during brain ischemia for several reasons. The massive release of excitatory amino acids (glutamate, aspartate) that occurs in brain during ischemia (Hagberg et al., 1985) has been im plicated in the induction of ischemic cell damage (Rothman, 1984; Choi, 1985) . Application of gluta mate antagonists has been shown to protect against acute ischemic and anoxic brain injuries (Simon et al., 1984; Gill et al., 1987) . Adenosine attenuates the release of glutamate (Dolphin and Archer, 1983; Fastbom and Fredholm, 1985) and provided that it is present in sufficient amounts should exert pro tective effects both by reducing excitotoxic amino acid release and by reducing the postsynaptic depo larization elicited by these agents. 2-Chloroadeno sine, a stable analog of adenosine, has recently been shown to prevent the loss of rat striatal neu rons after injections of kainic acid (Arvin et al., 1987) and another analogue, cyclohexyladenosine, enhanced gerbil survival after severe ischemia (Lu bitz et al., 1987) .
By reducing the formation of hypoxanthine, deoxycoformycin would eliminate the substrate for xanthine oxidase and thus the formation of toxic oxygen free radicals by this enzyme during reperfu sion (Chambers et al., 1985; Hearse et al., 1986; Cerchiari et al., 1987) . Finally, by preventing the metabolism of adenosine and inosine to uric acid, deoxycoformycin acts to conserve these purines for resynthesis into ATP, once oxidative metabolism has been reestablished. Deoxycoformycin therefore offers several interesting possibilities for prophy laxis against, and treatment of, cerebral injury as sociated with stroke or cardiac arrest.
